Blume-Jensen Peter 4

What Happened

• Dr. Peter Blume-Jensen, President, CEO and a director of Acrivon Therapeutics (ACRV), received two restricted stock unit (RSU) awards on 2026-05-18: 180,095 RSUs and 72,706 RSUs, for a total of 252,801 RSUs. Each RSU represents a contingent right to one share; the awards were granted with an acquisition price of $0 (transaction code A).

Key Details

• Transaction date: 2026-05-18; Form 4 filed: 2026-05-20 (filed within the typical two-business-day window).
• Awards: 180,095 RSUs and 72,706 RSUs (total 252,801 RSUs); price recorded $0 (standard for RSU grants).
• Vesting (per footnote): 16.67% of RSUs vest on November 18, 2026; remaining RSUs vest in 10 substantially equal quarterly installments thereafter, subject to continuous service through each vesting date.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Related-party notes: filings include spousal holdings/disclaimers — Dr. Blume-Jensen and his spouse, Dr. Kristina Masson (co‑founder and EVP), are referenced in footnotes; each disclaims beneficial ownership of the other's securities except to the extent of pecuniary interest.

Context

• RSU grants are compensation awards that convert to shares only as they vest; no cash was exchanged and there was no immediate sale. Such awards are routine executive compensation and do not by themselves indicate a buy/sell signal.